timothy sykes logo
SCNI Regains Nasdaq Compliance As Traders Refocus On Growth Thumbnail
G Google News

SCNI Regains Nasdaq Compliance As Traders Refocus On Growth

TIM SYKES•UPDATED OCT. 13, 2026, 12:32 PM ET
Reviewed by Jack Kelloggand Fact-checked by Ellis Hobbs

Scinai Immunotherapeutics Ltd. stocks have been trading up by 14.22 percent amid heightened optimism from its latest therapeutic developments

Key Takeaways

  • Nasdaq has confirmed that Scinai Immunotherapeutics is back in compliance with the $1.00 minimum bid requirement, taking delisting risk off the table for now.
  • Compliance followed 19 straight trading days with SCNI closing above the $1.00 mark, signaling near-term price stabilization.
  • The company is pressing ahead with its NanoAb immunology programs as a core value driver beyond the listing headline.
  • Management is also pushing to expand Scinai’s CDMO operations, aiming to leverage existing infrastructure for fee-based revenue.

Candlestick Chart

Live Update At 12:32:10 EDT: On Tuesday, October 13, 2026 Scinai Immunotherapeutics Ltd. stock [NASDAQ: SCNI] is trending up by 14.22%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

SCNI has been trading like a classic low‑float biotech trying to find its footing after a regulatory overhang. Over the last several sessions, Scinai Immunotherapeutics has faded from a recent push near $2.00 down toward the mid‑$1.00s, closing around $1.33 on 2026/10/13. That’s still above Nasdaq’s key $1.00 line in the sand, but it shows traders locking in profits after a sharp run.

Looking at the bigger picture, Scinai Immunotherapeutics generated about $1.31M in revenue, with a price‑to‑sales ratio near 1.22. For a small-cap biotech, that’s relatively modest, but it suggests the market isn’t assigning wild, bubble‑style expectations to SCNI right now. Book value per share sits around $1.83, while SCNI trades at a discount to that level, with a price‑to‑book near 0.64. Traders watching deep‑value setups will notice that.

More Breaking News

On the flip side, returns on assets and equity are sharply negative, reflecting a company still burning capital to build its platform. Scinai Immunotherapeutics carries total assets of roughly $11.6M, including about $1.66M in cash and $9.6M in property and equipment, which backs its CDMO capabilities. With 31 employees and leverage that’s not extreme, SCNI looks like a small, focused operator where execution matters more than balance‑sheet fireworks.

Why Traders Are Watching SCNI After Nasdaq Relief

The real story for traders is not just that Scinai Immunotherapeutics regained Nasdaq compliance. It’s how SCNI got there, and what the price action says about sentiment going forward. The company cleared the $1.00 minimum bid requirement after 19 straight trading days above that level, which doesn’t happen by accident. That stretch signals persistent demand and at least a baseline of confidence from the trading crowd.

On 2026/10/13, SCNI’s intraday action told the tale of a cleanup move after a big news spike. The stock ripped in premarket from roughly $1.13 to a high above $3.00, then pulled back hard, finally consolidating in the low‑$1.30s by midday. For Scinai Immunotherapeutics, that kind of blow‑off and retrace is textbook momentum behavior: early shorts get squeezed on the headline, late longs chase the move, and then reality sets in as day traders lock profits.

From here, the delisting cloud is gone, which matters a lot for small caps. With Nasdaq confirming compliance, SCNI no longer trades under the shadow of a potential forced exit from a major exchange. That reduces headline risk and lets short‑term traders refocus on the two real drivers: the NanoAb immunology pipeline and the contract development and manufacturing (CDMO) business.

Traders who follow biotech know that platform stories like Scinai Immunotherapeutics tend to trade in waves around catalysts. Any concrete progress update on NanoAb programs, or new CDMO contracts leveraging SCNI’s $9.6M of production equipment, can become the next spark. Until then, price action and the $1.00 floor remain the key reference points.

Conclusion

For active traders, SCNI has shifted from “can this stay listed?” to “what’s the next catalyst?” That’s a major sentiment change. Scinai Immunotherapeutics has removed the immediate risk of Nasdaq delisting by holding its bid above $1.00 for 19 consecutive trading days, and the exchange has formally closed the matter. That alone can attract more day traders and swing traders who avoid regulatory headaches.

Now the market cares less about paperwork and more about execution. Scinai Immunotherapeutics needs to show that its NanoAb immunology programs are progressing and that its CDMO operations can bring in steady, fee‑based revenue. With SCNI trading below book value and still well off its premarket highs, the stock sits in a zone where both long‑bias and short‑bias traders will be hunting setups.

Risk remains high. Negative returns on capital and a small cash pile mean Scinai Immunotherapeutics must manage its runway carefully. But the tape has already shown SCNI can move fast when news hits, and the Nasdaq compliance win proves there is real buying interest when headlines line up.

As Tim Sykes loves to say, “The market rewards prepared traders.” As millionaire penny stock trader and teacher Tim Sykes, says, “You must adapt to the market; the market will not adapt to you.”. For SCNI, that means knowing the compliance story, mapping the support around $1.00, and being ready if NanoAb or CDMO headlines trigger the next momentum surge. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”